Haleon plc stock (GB00BMX86B70): Consumer health group updates investors amid steady demand

Haleon plc, the consumer health group behind brands like Sensodyne and Voltaren, has updated investors with its latest trading developments and guidance as demand for everyday health products remains resilient in key markets.

Haleon plc, a pure-play consumer health company with brands such as Sensodyne, Voltaren and Centrum, recently updated investors on its current trading and outlook as part of its latest reporting cycle. Management highlighted continued demand for over-the-counter medicines and oral health products, while also flagging ongoing cost pressures and foreign exchange headwinds, according to the company’s investor materials and recent communications as of April 2025, cited by outlets including Reuters as of 04/17/2025.

As of: 24.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Haleon
• Sector/industry: Consumer health, over-the-counter medicines, oral care
• Headquarters/country: Weybridge, United Kingdom
• Core markets: Europe, North America, emerging markets in Asia and Latin America
• Key revenue drivers: Over-the-counter pain relief, oral health, vitamins and supplements, respiratory care
• Home exchange/listing venue: London Stock Exchange (ticker: HLN), secondary listing on NYSE (ticker: HLN)
• Trading currency: Primarily GBP in London; USD on NYSE

Haleon plc: core business model

Haleon plc was created as a standalone consumer health business following its spin-off from a large pharmaceutical group. The company focuses on branded over-the-counter products that cater to everyday health needs, from pain relief and oral care to vitamins and respiratory treatments, as outlined in its corporate profile and IPO documentation published in July 2022 and updated in subsequent annual reports as of March 2024, referenced by Haleon investor information as of 03/28/2024.

The business model centers on developing, marketing and distributing consumer health brands that enjoy strong recognition and repeat usage. Haleon typically positions its products at the intersection of consumer goods and healthcare, relying on a mix of pharmacy channels, mass retail, e-commerce and healthcare professional recommendations. This model aims to combine the resilience of everyday necessities with the pricing power of trusted healthcare brands, according to the company’s strategic presentations and capital markets day materials as of November 2023.

Haleon’s portfolio spans several major categories. In oral health, brands such as Sensodyne and Parodontax target sensitive teeth and gum disease. In pain relief and inflammation, Voltaren and Panadol address chronic and acute pain conditions. In vitamins, minerals and supplements, brands like Centrum provide daily nutrition support. There are also respiratory brands focused on cold, flu and allergy symptoms, as well as products for digestive health and other specialty niches, as outlined in the group’s 2023 annual report published in March 2024 and summarized by Financial Times as of 03/30/2024.

The company emphasizes innovation and incremental product improvements, often launching new formulations, delivery formats or indications under established brand umbrellas. This approach seeks to extend the lifecycle of key brands, defend shelf space and capture premium pricing. At the same time, Haleon uses targeted marketing campaigns, digital outreach and partnerships with healthcare professionals to reinforce brand trust in both developed and emerging markets.

Main revenue and product drivers for Haleon plc

Haleon’s revenue base is diversified across categories but concentrated in a handful of global brands. Oral health is a major pillar, with Sensodyne frequently cited as a flagship asset. According to the company’s 2023 full-year results released in March 2024, oral health delivered mid-single-digit organic revenue growth for the year, supported by increased penetration in key markets and line extensions that address different sensitivity and whitening needs, as reported by Reuters as of 03/01/2024.

Pain relief and anti-inflammatory products form another core revenue stream. Voltaren, a topical anti-inflammatory, and Panadol, a widely used pain reliever, both benefit from aging populations and the desire to manage chronic conditions without prescription medicines in many cases. Haleon has highlighted that demographic trends and greater focus on self-care are structural supports for this category. However, the company also notes that competition is intense, and pricing actions need to be balanced against affordability given a mixed macroeconomic backdrop, as described in its full-year 2023 earnings presentation published in March 2024.

Vitamins, minerals and supplements (VMS) are a third key pillar. Centrum and other supplement brands benefit from rising consumer interest in immunity, wellness and preventive health. Demand for VMS products saw a significant boost during and after the COVID-19 pandemic, and while growth rates have normalized, Haleon’s management has indicated that underlying consumption patterns remain above pre-pandemic levels. In its 2023 annual report, the company stated that VMS delivered solid organic growth, supported by targeted innovations and expanded distribution in select emerging markets, according to Haleon results and reports as of 03/28/2024.

Regional diversification also plays a significant role. Europe and North America together account for a large share of sales, but emerging markets in Asia and Latin America are increasingly important. These regions offer higher long-term growth potential as incomes rise and access to modern retail channels expands. The company has reported double-digit organic growth in some emerging markets in recent periods, albeit from a lower base, while acknowledging that currency volatility and regulatory complexity can weigh on reported results, as noted in its half-year 2024 trading update published in August 2024 and summarized by Bloomberg as of 08/01/2024.

Conclusion

Haleon plc positions itself as a focused consumer health business with a portfolio of well-known brands and a broad geographic footprint. Recent updates underline steady demand in oral health, pain relief and vitamins, despite cost inflation and currency swings that can affect margins and reported growth. For US investors, the dual listing on the NYSE provides direct access to a company that sits at the intersection of healthcare and consumer staples. At the same time, the group faces competitive pressure, regulatory complexity and the need for continued innovation to sustain brand strength, which remain key factors to monitor alongside broader macroeconomic and consumer spending trends.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.